GOODWILL(688246)2025-02-27 08:10Financial Performance - The total revenue for 2024 was RMB 60,072.44 million, a decrease of 13.59% compared to the previous year[4] - The net profit attributable to the parent company was RMB -14,997.36 million, representing a decline of 452.90% year-on-year[4] - The net profit attributable to the parent company after deducting non-recurring gains and losses was RMB -15,630.23 million, down 538.23% from the previous year[4] - The basic earnings per share were RMB -1.09, a decrease of 451.61% compared to the previous year[4] Assets and Equity - Total assets at the end of the reporting period were RMB 261,729.46 million, a decrease of 1.12% year-on-year[6] - The equity attributable to the parent company was RMB 167,426.82 million, down 8.77% from the previous year[6] Research and Development - The company maintained high R&D investment, focusing on AI technology exploration and product iteration, with plans to release a new version of the intelligent electronic medical record platform in early 2025[11] Investment and Losses - The company faced significant losses from its associate company, Beijing Ande Medical Technology Co., Ltd., which impacted the investment loss recognized by the company[10] Revenue Decline Factors - The decline in revenue was attributed to delayed customer demand, prolonged bidding processes, and extended delivery cycles due to the overall economic and medical industry environment[7] - The company has increased its asset impairment provisions significantly due to the extended collection periods from hospital clients[9]